Social Media Monitoring Report on Hemlibra, a drug by Roche, Inc. for Hemophilia A
Research Study Background
Roche developed drug, Hemlibra (emicizumab) got US FDA marketing approval on 16th Nov 2017 for adult patients with Hemophilia A.
Hemlibra is a bispecific factor IXa- and factor X-directed antibody which was approved on the basis of clinical data from phase III clinical trial where Hemlibra showed significant improvement in hemophilia-related symptoms and physical functioning. The FDA granted application Hemlibra also received Orphan Drug designation.
Roche got Prior marketing authorization for Hemlibra under Priority Review and Breakthrough Therapy designations.
Findings:
Sentiment Analysis on Hemlibra Drug Approval
Positive: Hemlibra approval was quoted as a landmark breakthrough - “Amazing news for #Hemophilia A #patients ! #Hemlibra approval #FDA #biotech #Pharma”- HCP
Negative: Some were found concerned about Hemlibra safety and commercial session and reflected negatively on social media channels – “Did I miss something or shouldn't the #FDA have held an adcomm session for emicizumab (Hemlibra)? Serious safety issue, black box, Shire toe-to-toe on data. Needed public hearing.”- Journalist
Neutral: Majority of healthcare practitioners were either neutral or positive about the approval and found sharing the information on social media - “FDA approves Hemlibra, a new treatment to prevent bleeding in people w/ hemophilia A and Factor VIII inhibitors“- HCP
Contact us for qualitative social media monitoring and social media intelligence research/reports.